End of the Road for Eleclazine and Liberty HCM Study

 Eleclazine:  The Liberty HCM Trial

It appears to be the end of the road for the Gilead drug eleclazine, a late sodium channel inhibitor previously known as GS-6615.  Eleclazine, with properties similar to the anti-angina drug ranolazine (which was approved by the FDA in 2006), was the subject of a recently terminated HCM clinical trial known as Liberty-HCM.  The HCM eleclazine study focused on whether the drug would improve symptoms and exercise capacity in patients with HCM by increasing their peak oxygen uptake, resulting in improved VO2 max readings on exercise testing.  The HCM study began enrolling patients in February 2015. Data collection had been scheduled to continue through June 2017. Continue reading “End of the Road for Eleclazine and Liberty HCM Study”

BNP and Troponin Levels in HCM: USEFULNESS OF BLOOD TESTS 

gringer-Blood-tube-vaccuum-style

 Image by Ocal - http://www.clker.com/clipart-13766.html

Doctors from Cedars-Sinai Hospital Center for HCM and Aortopathies say that certain blood test results  – specifically BNP and Troponin levels – are useful in evaluating HCM patients, particularly with respect to risk stratification and guidance of medical therapy.